Clinical Trials Browser

Phase 3 × Lutetium-177 × Gastrointestinal × Clear all

NCT05884255 2026-04-17

An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.

Phase 3 Recruiting

EndocrineGastrointestinalNET

Advanced Gastroenteropancreatic Neuroendocrine Tumor